|
HER2 gene amplification
|
0.100 |
Biomarker
|
disease |
BEFREE |
TOP2A gene amplification was significantly associated with HER2 gene amplification.
|
19061514 |
2008 |
|
HER2 gene amplification
|
0.100 |
Biomarker
|
disease |
BEFREE |
In multivariate analysis, TOP2A amplification (odds ratio [OR] 3.04, P = 0.021), but not HER2 amplification (OR 1.74, P = 0.170) was associated with a significantly higher pCR rate.
|
20130985 |
2010 |
|
HER2 gene amplification
|
0.100 |
Biomarker
|
disease |
BEFREE |
HER2 amplification was found in 23.7% of the patients and TOP2A amplification in 10.1%.
|
23537287 |
2013 |
|
HER2 gene amplification
|
0.100 |
Biomarker
|
disease |
BEFREE |
Correlation between ER, PR, HER-2, Bcl-2, p53, proliferative and apoptotic indexes with HER-2 gene amplification and TOP2A gene amplification and deletion in four molecular subtypes of breast cancer.
|
24272208 |
2014 |
|
HER2 gene amplification
|
0.100 |
Biomarker
|
disease |
BEFREE |
In a subset of specimens selected for fluorescence in situ hybridization analysis of TOP2A and HER2/neu amplification using a recently developed multicolor probe, 7 of 8 lesions with an NLI of 25% or more demonstrated TOP2A amplification, in contrast with 2 of 14 lesions with a TOP2A NLI of less than 25%.
|
15762277 |
2005 |
|
HER2 gene amplification
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
HER-2 amplification was detected in 11 patients (22%) and TOP2A changes were seen in 6 patients (12%); two amplifications and two deletions were observed in HER-2-amplified cases and two deletions in HER-2-nonamplified cases.
|
17922046 |
2007 |
|
HER2 gene amplification
|
0.100 |
Biomarker
|
disease |
BEFREE |
Assessment of HER-2 gene amplification and TOP2A gene amplification/deletion was made by FISH analysis using the LSI TOP2A/HER-2/CEP 17 multicolor probe or the LSI HER-2/CEP dual color probe (Vysis, Downers Grove, IL, USA) in formalin-fixed and paraffin-embedded tissue sections of 54 breast cancer patients who were grouped into stages 1+, 2+ or 3+ based on IHC (HercepTest; DakoCytomation, Carpinteria, CA, USA) observations.
|
17638622 |
2007 |
|
HER2 gene amplification
|
0.100 |
Biomarker
|
disease |
BEFREE |
TOP2A amplification in the absence of HER-2 amplification may be associated with lower histological grade and ER positivity.
|
14632728 |
2003 |
|
HER2 gene amplification
|
0.100 |
Biomarker
|
disease |
BEFREE |
HER2 amplification was seen in 101 of 628 (16.1 %) and TOP2A amplification in 32 (5.1 %) cancers.
|
24682655 |
2014 |
|
HER2 gene amplification
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Using previously collected data for HER2 amplification and TOP2A gene aberrations, we defined patients as "anthracycline non-responsive", that is, 2T (TIMP-1 immunoreactive and TOP2A normal) and HT (TIMP-1 immunoreactive and HER2 negative) and anthracycline responsive (all other cases).
|
23570501 |
2013 |
|
HER2 gene amplification
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
HER2 and TOP2A amplification did not share the same effects on their downstream molecules, with consistent patterns observed in HER2 mRNA and protein expression according to HER2 amplification (all parameters strongly inter-related, p values < 0.001), but inconsistent patterns in the case of TOP2A.
|
22240029 |
2012 |
|
HER2 gene amplification
|
0.100 |
Biomarker
|
disease |
BEFREE |
In univariate analyses, only HER2 amplification and TOP2A deletion were significant prognostic factors for relapse-free (hazard ratio [HR] 1.59, 95% CI 1.32-1.92, p<0.0001; and 1.52, 1.20-1.92, p=0.0006, respectively) and overall survival (1.79, 1.47-2.19, p<0.0001; and 1.62, 1.26-2.08, p=0.0002 respectively).
|
20079691 |
2010 |
|
HER2 gene amplification
|
0.100 |
Biomarker
|
disease |
BEFREE |
C-myc and HER2 amplification were examined by FISH, and oestrogen receptor (ER), progesterone receptor (PR), Ki67, and topoisomerase 2α (TOP2A) expression were examined immunohistochemically.
|
21741827 |
2011 |
|
HER2 gene amplification
|
0.100 |
Biomarker
|
disease |
BEFREE |
TOP2A amplification was restricted to tumours with HER2 amplification and was significantly associated with ER positivity.
|
17260090 |
2007 |
|
HER2 gene amplification
|
0.100 |
Biomarker
|
disease |
BEFREE |
During the first 5 years after diagnosis, the risk of death from breast cancer was significantly higher for cases with HER2 amplification irrespective of TOP2A status.
|
24403186 |
2014 |
|
HER2 gene amplification
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Of the 137 cases with HER2 amplification, 23 (16%) showed a monoallelic deletion of TOP2A .
|
15891995 |
2005 |
|
HER2 gene amplification
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Simultaneous amplification of both genes was found in 28% of the abnormal tumors (12% of all patients) while TOP2A deletion and ERBB2 amplification was observed in 16% of the abnormal cases (8% of all patients).
|
19945923 |
2010 |
|
HER2 gene amplification
|
0.100 |
Biomarker
|
disease |
BEFREE |
Subgroup analysis showed no significant differences of OS and DFS either between TOP2A-positive and TOP2A-negative groups or between TOP2A amplification and control group in population of patients with HER-2 amplification, triple negative breast cancer, or hormone-positive breast cancer.
|
25846735 |
2015 |
|
HER2 gene amplification
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Eight primary tumors with high-level ERBB2 amplification showed a new type of intratumoral heterogeneity; two different cell clones with either high-level amplification or deletion of TOP2A were found adjacent to each other in the same tumor.
|
10469452 |
1999 |
|
HER2 gene amplification
|
0.100 |
Biomarker
|
disease |
BEFREE |
High rates (>40%) of HER2 amplification were seen in patients with TOP2A amplification in breast, ovarian, gastroesophageal/oesophageal and pancreatic cancer.
|
28728050 |
2017 |
|
HER2 gene amplification
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The topoisomerase IIalpha gene, TOP2A, is located adjacent to the HER-2 oncogene at the chromosome location 17q12-q21 and is either amplified or deleted (with equal frequency) in a great majority of HER-2 amplified primary breast tumors and also in tumors without HER-2 amplification.
|
17100565 |
2006 |
|
HER2 gene amplification
|
0.100 |
Biomarker
|
disease |
BEFREE |
TOP2A amplification is statistically associated with age >50 at diagnosis (P = 0.016) and HER2 amplification (P < 0.001).
|
28079792 |
2017 |
|
HER2 gene amplification
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
TOP2A gene alterations were found in 22.6% (21.0% of cases with amplification and 1.6% with deletion), and these tumors were biologically more aggressive, with higher nuclear grade, more frequently with HER2 amplification and inflammatory type.
|
25042383 |
2014 |
|
HER2 gene amplification
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The results showed no correlation between TOP2A gene copy number and topoisomerase II alpha protein expression levels in breast tumors, in contrast to the analogous situation for HER2 gene amplification and HER2 immunohistochemistry.
|
14978790 |
2004 |
|
HER2 gene amplification
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, our study points to the importance of FISH examination of TOP2A gene status in all tumors with ERBB2 amplification.
|
17013533 |
2006 |